纯度95%，200 mg
实单询价
化合物简介
Crenolanib besylate (CP-868,596-26; 4-piperidinamine, 1-[2-[5-[(3-Methyl-3-oxetanyl) methoxy]-1H-benzimidazol-1-yl]- 8-quinolinyl]-, monobenzenesulfonate) is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzamidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR α (Platelet-Derived Growth Factor Receptor), and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the ‘DFG in’ conformation motif.
基本信息
- 中文名称：
- [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺
- 中文别名：
- 罗通定.左旋延胡索乙素
- 英文名称：
- 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
- 英文别名：
- Crenolanib [USAN:INN];
ARO-002;
Crenolanib;
Crenolanib;
1-{2-[5-(3-methyloxetan-3-ylmethoxy)benzoimidazol-1-yl]quinolin-8-yl}piperidin-4-ylamine;
- CAS号：
- 670220-88-9
- 分子式：
- C26H29N5O2
- 分子量：
- 443.54100
- 精确质量：
- 443.23200
- PSA：
- 78.43000
- LogP：
- 4.68180
物化性质
- 密度：
- 1.36
